Center-Authored Papers

Filters: Author is Kauh, John S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D et al..  2016.  Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
S
Saif MW, Knost JA, Chiorean GE, Kambhampati SRP, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH.  2016.  Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.. Cancer chemotherapy and pharmacology. 78(4):815-824. Abstract
Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S et al..  2015.  Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.. Investigational new drugs. 33(3):652-63. Abstract